All News
Rheumatoid Arthritis Offspring Show Normal School Performance
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.
Read Article
FDA Approves Anifrolumab in SLE
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
Read Article
"Fibromyalgianess" is highlighted as a risk factor for undue, extended glucocorticoid use in rheumatoid arthritis (RA) patients, according to Wallace and colleagues in Rheumatology.
https://t.co/uv19GSZsBV https://t.co/aSFlV9zeGt
Links:
Dr. John Cush RheumNow ( View Tweet)
Article in press:
Can ANCA titers predict relapse in patients with GPA?
Cohort study by @UofT_DoM
- microscopic hematuria and MPO ab at month 12 predicted increased risk of relapse
https://t.co/ks3Gj5iSLR
Seminars in Arthritis and Rheumatism seminarthrheum ( View Tweet)
Study from the UK BSRBR for #AS & 2043 pts showed 44% w/ at least 1 comorbidity. Each comorbidity was associated w/ 0.40 unit increase in BASDAI and 0.53 in spinal pain. More Dz activity w/ Depression, CHF and peptic ulcer, not CRP/ESR https://t.co/0vAnbjHicw
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Anifrolumab in active, moderate-severe SLE on background standard of care therapies. https://t.co/22HVA32IAh https://t.co/NxJ4sWTWfE
Dr. John Cush RheumNow ( View Tweet)
Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.
https://t.co/Uu1VjAbKMi https://t.co/uGvTyLExjf
Links:
Dr. John Cush RheumNow ( View Tweet)
The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).
https://t.co/RNWrLR53Wx https://t.co/mMmKKrX9vx
Links:
Dr. John Cush RheumNow ( View Tweet)
Health personnel (HCP) @ long-term care facilities (LTCFs) are at high risk for COVID-19. March 2021, 57% of LTCF HCPs were vaccinated. COVID-19 vax was highest in MDs (75.1%); lowest nurses (56.7%) & aides (45.6%). https://t.co/VjHutcrh26 https://t.co/8aO1mFgC8f
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: The FDA has authorized baricitinib ALONE as treatment for COVID-19 hospitalized adults and pediatric patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) https://t.co/WMc78GmOLU https://t.co/Bp5tL4pRk5
Links:
Dr. John Cush RheumNow ( View Tweet)
Worth another share--
Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021
https://t.co/S0ownscRKv https://t.co/7QtynRKAd6
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: One of our top June videos
WATCH: Is blindness with Tocilizumab in GCA a worry?
Dr. David Liew ( @drdavidliew ) weighs in. #EULAR2021
https://t.co/eFrmbkW9Gy https://t.co/4tY3hEDj2j
Links:
Dr. John Cush RheumNow ( View Tweet)
Pain Persists in RA, Even Without Inflammation
One-third of patients with rheumatoid arthritis had unacceptably high levels of pain 5 years after diagnosis, often despite low levels of inflammation, Swedish researchers found.
https://t.co/K8zf1pE9jM https://t.co/aEBu7jVHft
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Psoriatic Arthritis Without Psoriasis
Download wherever you get your podcasts!
https://t.co/Ra5f7507XT https://t.co/5WqPCgGVpr
Links:
Dr. John Cush RheumNow ( View Tweet)
Did you see this tweet from May? Worth re-sharing.
Rituximab Tops Mycophenolate Mofetil for Pemphigus Vulgaris. One year study of 135 moderate-to-severe pemphigus patients saw complete remission in 40% of RTX vs 10% of MMF patients. https://t.co/yAauFRjHCe https://t.co/bibHXaHtWf
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast available for download! We focus on the articles shared this week on https://t.co/V10S4oVFsv .
https://t.co/Ra5f7507XT https://t.co/Pz0RFxLIOx
Dr. John Cush RheumNow ( View Tweet)
Swiss SCQM registry compared 3217 RA & 819 PsA pts; PsA had more obese (36.5% overweight, 23.8% obese) than RA (4.4% underweight, 31.8% overweight, 17.0% obese). Obese PsA had higher CRP, Dz activity, worse QOL, pain & skin https://t.co/UzbKlT3tSz
Links:
Dr. John Cush RheumNow ( View Tweet)
Literature review examined safety of IL-17 inhibitors in 106 controlled RCTs, 40,053 pts. Inflammatory bowel disease was reported in 0.4% of IL-17i Rx patients. (same in 61 uncontrolled RCTs -0.36%). Other AE: diarrhea (2.5%), N/V(0.7%) https://t.co/2wSZQqB1Zs
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA article on using new features in Updated PubMed:
1) Focus the Clinical Question
2) Use PubMed Clinical Query Filters
3) Refine the Search Terms
https://t.co/ExK8p2hVnX
Links:
Dr. John Cush RheumNow ( View Tweet)